CN102791724A - 用于医疗用途的一氧化碳释放铼化合物 - Google Patents

用于医疗用途的一氧化碳释放铼化合物 Download PDF

Info

Publication number
CN102791724A
CN102791724A CN2011800130211A CN201180013021A CN102791724A CN 102791724 A CN102791724 A CN 102791724A CN 2011800130211 A CN2011800130211 A CN 2011800130211A CN 201180013021 A CN201180013021 A CN 201180013021A CN 102791724 A CN102791724 A CN 102791724A
Authority
CN
China
Prior art keywords
group
alkyl
acyl
alkoxycarbonyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800130211A
Other languages
English (en)
Chinese (zh)
Inventor
F·佐比
R·阿尔佩托
L·克罗默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN102791724A publication Critical patent/CN102791724A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
CN2011800130211A 2010-03-08 2011-03-04 用于医疗用途的一氧化碳释放铼化合物 Pending CN102791724A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10002342 2010-03-08
EP10002342.3 2010-03-08
PCT/EP2011/001077 WO2011110315A1 (en) 2010-03-08 2011-03-04 Carbon monoxide releasing rhenium compounds for medical use

Publications (1)

Publication Number Publication Date
CN102791724A true CN102791724A (zh) 2012-11-21

Family

ID=43828395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800130211A Pending CN102791724A (zh) 2010-03-08 2011-03-04 用于医疗用途的一氧化碳释放铼化合物

Country Status (6)

Country Link
US (2) US9512156B2 (https=)
EP (1) EP2545064B1 (https=)
JP (1) JP5919202B2 (https=)
CN (1) CN102791724A (https=)
CA (1) CA2792319A1 (https=)
WO (1) WO2011110315A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628634T3 (es) * 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
EP2868348A1 (en) 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) * 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
US20070207217A1 (en) 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CA2534415A1 (en) * 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
EP2196222B1 (en) * 2003-10-20 2014-04-23 Universität Zürich Tricarbonyl complexes of rhenium comprising amino acids as bidentate ligands and their use as radiotherapeutic chemotoxic agents.
AU2005205126A1 (en) * 2004-01-08 2005-07-28 Universitat Zurich Metal complexes having vitamin B12 as a ligand
US20070207993A1 (en) 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
JP5563452B2 (ja) 2007-07-24 2014-07-30 アルファーマ−インベスティガシオ エ デセンボルビメント デ プロデュトス ファルマセウティコス エレデア． 一酸化炭素による胃潰瘍の予防

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FABIO ZOBI ET AL.: "CO Releasing Properties and Cytoprotective Effect of cis-trans- [ReII(CO)2Br2L2]n Complexes", 《INORGANIC CHEMISTRY》 *
FABIO ZOBI ET AL.: "Synthesis and Reactivity of the 17e- Complex [ReIIBr4(CO)2]2-: A Convenient Entry into Rhenium(II) Chemistry", 《INORGANIC CHEMISTRY》 *
LUKAS KROMER ET AL.: "Substitution reactions with [ReBr2(CO)2(NCCH3)2]-: a convenient route to complexes with the cis-[Re(CO)2]+ core†", 《DALTON TRANSACTIONS》 *
LUKAS KROMER ET AL.: "Substitution reactions with [ReBr2(CO)2(NCCH3)2]-: a convenient route to complexes with the cis-[Re(CO)2]+ core†", 《DALTON TRANSACTIONS》, no. 42, 15 September 2008 (2008-09-15), pages 5800 - 5806, XP002633051, DOI: doi:10.1039/b805410j *
MICHAEL G. B. DREW: "PHOSPHINE CONTAINING RHENIUM(IIl) CARBONYL COMPLEXES. THE CRYSTAL AND MOLECULAR STRUCTURE OF TRIBROMODICARBONYLBIS(DIMETHYLPHENYLPHOSPHINE)RHENIUM(III)", 《POLYHEDRON》 *
SUSANNE KUNZE ET AL.: "Vitamin B12 as a Ligand for Technetium and Rhenium Complexes", 《BIOINORGANIC CHEMISTRY》 *
ZINGALES ET AL.: "Halogen-Bridged Rhenium Carbonyl Nitrosyl Complexes and Derivatives", 《INORGANIC CHEMISTRY》 *

Also Published As

Publication number Publication date
EP2545064A1 (en) 2013-01-16
US20120328712A1 (en) 2012-12-27
JP2013521316A (ja) 2013-06-10
CA2792319A1 (en) 2011-09-15
WO2011110315A1 (en) 2011-09-15
EP2545064B1 (en) 2020-05-06
US9512156B2 (en) 2016-12-06
JP5919202B2 (ja) 2016-05-18
US20170071981A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
DE69224839T2 (de) Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
AU2008269094B2 (en) Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
Wilson et al. Synthesis, characterization, and cytotoxicity of platinum (IV) carbamate complexes
EP3416633B1 (en) Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors
KR101915452B1 (ko) 백금 화합물, 조성물 및 이의 용도
TW201034691A (en) Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof
TW202144369A (zh) 海鞘素類衍生物及其製備方法與醫藥用途
CN103896970B (zh) 2-吡啶甲醇铜配合物及制备方法和应用
CN112351979B (zh) Rip1抑制剂及其在医药中的用途
TW201400477A (zh) 單環雜芳基環烷二胺衍生物
CN108264510A (zh) 一种选择性抑制激酶化合物及其用途
RS64535B1 (sr) Farmaceutska kompozicija jedinjenja koje sadrži azot ili njegovu so, ili njihov kompleks sa metalom
EP4171538A1 (en) Selective histone deacetylase 6 inhibitors
CN118126090A (zh) 一种铱配合物光敏剂及其制备方法和应用
CN102791724A (zh) 用于医疗用途的一氧化碳释放铼化合物
KR101683350B1 (ko) 신규한 4핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암 질환 예방 또는 치료용 약학 조성물
AU2015203742A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
Jung et al. Syntheses and First Crystal Structures of Rhenium Complexes Derived from ψ‐Functionalized Fatty Acids as Model Compounds of Technetium Tracers for Myocardial Metabolism Imaging
KR101065932B1 (ko) 방사선 치료 증강제
CN111057063B (zh) 一种用于急性淋巴细胞白血病的靶向光动力治疗的酞菁衍生物及其制备方法
KR101135789B1 (ko) 피리딘 유도체를 유효성분으로 하는 방사선 치료 증강제
CN108721618A (zh) Fe3O4@CuO@OxyHb@ZnPc@m-HA五元复合体系及其制备方法和应用
KR101973456B1 (ko) 미토콘드리아에 표적화되는 수용성 화합물, 이를 포함하는 조성물 및 이의 제조방법
Pham Covalent metal-organic networks, amine coordinated complex ions, and the synthesis of novel tryptamine compounds: a thesis in Chemistry
Wang et al. H2O2 self-supplying cascade nanocomposite for photothermally enhanced chemodynamic therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121121